Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer

PURPOSEKRAS p.G12C mutations occur in approximately 3% of metastatic colorectal cancers (mCRC). Recently, two allosteric inhibitors of KRAS p.G12C have demonstrated activity in early phase clinical...